Bipolar Coagulation Ablation and Endocardial Ablation Using Coagulation de Plasma Argon for Atrial Fibrillation Treatment in Patients With Rheumatic Heart Disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006193

Enrollment

Unknown

Registered

2015-03-12

Start date

2015-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Interventions

experimental group:bipolar radiofrequency ablation and coagulation de plasma argon

control group:bipolar radiofrequency ablation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The patients got atrial fibrillation with rheumatic heart disease need surgical radiofrequency ablation treatment aged from 18 to 65 years old.

Exclusion criteria

Exclusion criteria: left atrial diameter greater than 65mm, sick sinus syndrome, atrioventricular block, ventricular tachycardia, reoperation patients, implantation of permanent pacemaker, NYHA class IV, Malignant tumor, or other serious diseases which life expectancy <1 year, Heating temperature above 38 degrees or active infection.

Design outcomes

Primary

Measure	Time frame
electrocardiogram;surgery time;radiofrequency ablation time;rates of cardioversion of atrial fibrillation;long-term recurrence rate of atrial fibrillation;Left ventricular ejection fraction;doppler echocardiography;Left ventricular end-diastolic diameter;	—

Secondary

Measure	Time frame
cardiopulmonary bypass time;aortic crossclamp time;surgery time;complication after surgery;	—

Countries

China

Contacts

Public ContactLin Chen

chenlin_xq@aliyun.com+86 23 68774107

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026